上海谊众(688091.SH)2025年度归母净利润6413.2万元，同比增长819.42%

Core Viewpoint - Shanghai Yizhong (688091.SH) reported significant growth in its 2025 financial performance, driven by the inclusion of its core product, paclitaxel polymer micelles, in the national medical insurance catalog [1] Financial Performance - The company achieved an operating revenue of 317 million yuan in 2025, representing a year-on-year increase of 82.72% [1] - The net profit attributable to the parent company was 64.132 million yuan, showing a remarkable year-on-year growth of 819.42% [1] Product Impact - The inclusion of paclitaxel polymer micelles in the national medical insurance catalog significantly boosted market access and the number of patients using the product, contributing to the overall revenue and profit growth for the year [1]